The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

adarx.com

Founded Year

2019

Stage

Series B - II | Alive

Total Raised

$106.5M

Last Raised

$75M | 1 yr ago

About ADARx Pharmaceuticals

ADARx Pharmaceuticals is a next-wave genetic medicine company focused on the base editing of mRNA transcripts. ADARx Pharmaceuticals discovers and develops therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA to precise target and correct single point mutations on an mRNA, allowing the production of desired and functional proteins to be restored.

ADARx Pharmaceuticals Headquarter Location

5871 Oberlin DR Suite 200

San Diego, California, 92121,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ADARx Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ADARx Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest ADARx Pharmaceuticals News

ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology

Jun 7, 2022

June 07, 2022 09:20 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )-- ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology. “I am delighted to welcome Andrew to the ADARx team, as his wealth of experience in the biotech industry will greatly enhance our capabilities,” said Dr. Zhen Li, President and Chief Executive officer of ADARx. “Andrew has deep expertise across key aspects of development from preclinical studies to NDA submission and his leadership offers great benefit to the company as we continue to expand our pipeline and advance programs to the clinic.” Dr. Seacat has over 20 years of experience in nonclinical drug development, toxicology, and drug safety evaluation and, in his new role, will lead all GLP and non-GLP toxicology studies for our RNA-targeting therapeutics. Dr. Seacat was most recently Senior Director, Pharmacology and Toxicology at Zogenix (a wholly owned subsidiary of UCB S.A.) where he led authoring of all non-clinical sections of an NDA. Prior positions include Vice President, Preclinical Development at Latitude Pharmaceuticals and Senior Director, Preclinical Development at La Jolla Pharmaceuticals. He also had increasing roles of responsibility in toxicology and drug safety at Allergan Pharmaceuticals, Amylin Pharmaceuticals, and 3M Medical Department. Dr. Seacat received a Doctorate in Biochemical Molecular Toxicology and completed a Postdoctoral Fellowship at Johns Hopkins University. Dr Seacat was also Diplomate of the American Board of Toxicology (DABT2001-2015). About ADARx ADARx Pharmaceuticals, Inc. , located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases. ADARx lead programs are at IND-enabling stage. Contacts

ADARx Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ADARx Pharmaceuticals Rank

  • When was ADARx Pharmaceuticals founded?

    ADARx Pharmaceuticals was founded in 2019.

  • Where is ADARx Pharmaceuticals's headquarters?

    ADARx Pharmaceuticals's headquarters is located at 5871 Oberlin DR, San Diego.

  • What is ADARx Pharmaceuticals's latest funding round?

    ADARx Pharmaceuticals's latest funding round is Series B - II.

  • How much did ADARx Pharmaceuticals raise?

    ADARx Pharmaceuticals raised a total of $106.5M.

  • Who are the investors of ADARx Pharmaceuticals?

    Investors of ADARx Pharmaceuticals include OrbiMed Advisors, SR One, Lilly Asia Ventures and Sirona Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.